Engineering alginate-based dry powder microparticles to a size suitable for the direct pulmonary delivery of antibiotics
Resumen: The inhaled route is regarded as one of the most promising strategies as a treatment against pulmonary infections. However, the delivery of drugs in a dry powder form remains challenging. In this work, we have used alginate to form microparticles containing an antibiotic model (colistin sulfate). The alginate microparticles were generated by atomization technique, and they were characterized by antimicrobial in vitro studies against Pseudomonas aeruginosa. Optimization of different parameters allowed us to obtain microparticles as a dry powder with a mean size (Feret diameter) of 4.45 ± 1.40 µm and drug loading of 8.5 ± 1.50%. The process developed was able to concentrate most of the colistin deposits on the surface of the microparticles, which could be observed by SEM and a Dual-Beam microscope. This produces a fast in vitro release of the drug, with a 100% release achieved in 4 h. Physicochemical characterization using the FTIR, EDX and PXRD techniques revealed information about the change that occurs from the amorphous to a crystalline form of colistin. Finally, the cytotoxicity of microparticles was tested using lung cell lines (A549 and Calu-3). Results of the study showed that alginate microparticles were able to inhibit bacterial growth while displaying non-toxicity toward lung cells.
Idioma: Inglés
DOI: 10.3390/pharmaceutics14122763
Año: 2022
Publicado en: Pharmaceutics 14, 12 (2022), 2763 [19 pp.]
ISSN: 1999-4923

Factor impacto JCR: 5.4 (2022)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 50 / 278 = 0.18 (2022) - Q1 - T1
Factor impacto CITESCORE: 6.9 - Pharmacology, Toxicology and Pharmaceutics (Q1)

Factor impacto SCIMAGO: 0.795 - Pharmaceutical Science (Q1)

Financiación: info:eu-repo/grantAgreement/ES/MICINN/PID2019-108994RB-I00
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Ingeniería Química (Dpto. Ing.Quím.Tecnol.Med.Amb.)

Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.


Exportado de SIDERAL (2024-03-18-16:56:16)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos



 Registro creado el 2023-02-24, última modificación el 2024-03-19


Versión publicada:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)